Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis

References

• Kazmi WH, Kausz AT, Khan S, et al. Anemia: An early complication of chronic renal insufficiency. Am J Kidney Dis 2001;38:803–12
   PubMed Web of Science ®Google Scholar
• Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002;13: 504–10
   Google Scholar
• McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004;20:1501–10
   PubMed Web of Science ®Google Scholar
• Coresh J, Byrd-Holt D, Astor BC, et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol 2005;16: 180–88
   Google Scholar
• Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005;365:331–40
   PubMed Web of Science ®Google Scholar
• Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125–34
   PubMed Web of Science ®Google Scholar
• Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001;38: 955–62
   Google Scholar
• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296–305
   PubMed Web of Science ®Google Scholar
• Gouva C, Nikolopoulos P, Ioannidis JP, et al. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004;66:753–60
   PubMed Web of Science ®Google Scholar
• Dean BB, Dylan M, Gano A, Jr., et al. Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease. Curr Med Res Opin 2005;21:981–87
   PubMed Web of Science ®Google Scholar
• Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, et al. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 2006;69:560–64
   Google Scholar
• Gerson A, Hwang W, Fiorenza J, et al. Anemia and health-related quality of life in adolescents with chronic kidney disease. Am J Kidney Dis 2004;44:1017–23
   PubMed Web of Science ®Google Scholar
• Odden MC, Whooley MA, Shlipak MG. Association of chronic kidney disease and anemia with physical capacity: the heart and soul study. J Am Soc Nephrol 2004;15:2908–15
   Google Scholar
• Perlman RL, Finkelstein FO, Liu L, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis 2005;45:658–66
   PubMed Web of Science ®Google Scholar
• London R, Solis A, Goldberg GA, et al. Examination of resource use and clinical interventions associated with chronic kidney disease in a managed care population. J Manag Care Pharm 2003:9:248–55
   PubMedGoogle Scholar
• Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995;25:548–54
   PubMed Web of Science ®Google Scholar
• Hertel J, Locay H, Scarlata D, et al. Every-other-week (Q2W) Aranesp® (darbepoetin alfa) achieves and maintains target hemoglobin (Hb) levels and improves health-related quality of life (HRQOL) in recombinant human erythropoietin (rHuEPO)-naïve patients with chronic kidney disease (CKD). American Society of Nephrology Annual Meeting, Philadelphia, Pennsylvania, 2005
   Google Scholar
• USRDS: USRDS 2005 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD, 2005
   Google Scholar
• Toto RD, Pichette V, Navarro J, et al. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 2004;24:453–60
   PubMed Web of Science ®Google Scholar
• Suranyi MG, Lindberg JS, Navarro J, et al. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol 2003;23: 106–11
   PubMed Web of Science ®Google Scholar
• Hertel J, Locay H, Scarlata D, et al. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease (CKD) converting from once-weekly recombinant human erythropoietin (rHuEPO): results from simplify the treatment of anemia with Aranesp® (STAAR). Am J Nephrol 2006; 26: 149–56
   PubMed Web of Science ®Google Scholar
• Hertel JEW, Locay HR, Scarlata DS, et al. Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease. Mayo Clin Proc 2006;81:1188–94
   PubMed Web of Science ®Google Scholar
• Disney A, de Jersey P, Kirkland G, et al. A study of Aranesp^® (darbepoetin alfa) administered once monthly in anemic chronic kidney disease (CKD) patients. American Society of Nephrology Annual Meeting, St Louis, Missouri. 2004
   Google Scholar
• Ling B, Walczyk M, Agarwal A, et al. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol 63:327–34, 2005
   PubMed Web of Science ®Google Scholar
• Agarwal AK, Silver MR, Reed JE, et al. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease. J Intern Med 2006; in press.
   Google Scholar
• Macdougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol 2000;20:375–81
   PubMed Web of Science ®Google Scholar
• Egrie J, Browne J. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001;16(Suppl 3):3–13
   PubMed Web of Science ®Google Scholar
• Elliott S, Lorenzini T, Asher S, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003;21:414–21
   PubMed Web of Science ®Google Scholar
• Hertel J, Crawford P, Mafilios M, et al. Cost minimization model evaluating resource utilization to nephrology practices treating patients with erythropoietic stimulating protein (ESP) on a monthly (QM) versus weekly (QW) basis. National Kidney Foundation Annual Meeting, Chicago, Illinois, 2006
   Google Scholar
• Crawford P, Sholer C, Xu X, et al. Time associated with in office erythropoietic stimulating protein (ESP) injections for anemia in chronic kidney disease (CKD) patients. National Kidney Foundation Annual Meeting, Chicago, Illinois, 2006
   Google Scholar
• Bernardo M, Hertel J, Xu X, et al. Comparison of practice resources required to provide weekly (QW) versus monthly (QM) erythropoiesis stimulating protein (ESP) therapy. National Kidney Foundation Annual Meeting, Chicago, Illinois, 2006
   Google Scholar
• Richter A, Anton SE, Koch P, et al. The impact of reducing dose frequency on health outcomes. Clin Ther 2003;25:2307–35; discussion 2306
   Google Scholar
• US Aranesp® Package Insert: United States Aranesp® Package Insert. Amgen Inc., Thousand Oaks, California, USA, 2001
   Google Scholar
• Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461–70
   Google Scholar
• Moore T, Chookie S. Extended dosing of darbepoetin alfa in patients with chronic kidney disease not on dialysis: a review of recent data. Nephrol Nurs J 2005;32:399–407
   PubMedGoogle Scholar